Bedell Frazier Investment Counselling’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $372K | Sell |
7,646
-7,118
| -48% | -$346K | 0.09% | 85 |
|
|
2025
Q1 | $502K | Sell |
14,764
-6,349
| -30% | -$216K | 0.13% | 70 |
|
|
2024
Q4 | $831K | Sell |
21,113
-5,244
| -20% | -$206K | 0.21% | 67 |
|
|
2024
Q3 | $1.24M | Buy |
26,357
+218
| +0.8% | +$10.2K | 0.3% | 59 |
|
|
2024
Q2 | $1.41M | Buy |
26,139
+2,192
| +9% | +$118K | 0.34% | 60 |
|
|
2024
Q1 | $1.63M | Sell |
23,947
-29
| -0.1% | -$1.98K | 0.41% | 55 |
|
|
2023
Q4 | $1.5M | Sell |
23,976
-611
| -2% | -$38.2K | 0.41% | 51 |
|
|
2023
Q3 | $1.12M | Buy |
24,587
+182
| +0.7% | +$8.26K | 0.33% | 52 |
|
|
2023
Q2 | $1.37M | Sell |
24,405
-2,698
| -10% | -$151K | 0.4% | 49 |
|
|
2023
Q1 | $1.23M | Sell |
27,103
-559
| -2% | -$25.3K | 0.36% | 48 |
|
|
2022
Q4 | $1.12M | Sell |
27,662
-3,805
| -12% | -$155K | 0.29% | 55 |
|
|
2022
Q3 | $2.06M | Sell |
31,467
-2,920
| -8% | -$191K | 0.58% | 41 |
|
|
2022
Q2 | $2.09M | Buy |
34,387
+4,282
| +14% | +$260K | 0.64% | 41 |
|
|
2022
Q1 | $1.89M | Buy |
30,105
+3,216
| +12% | +$202K | 0.48% | 47 |
|
|
2021
Q4 | $2.04M | Buy |
26,889
+1,742
| +7% | +$132K | 0.5% | 49 |
|
|
2021
Q3 | $2.82M | Buy |
25,147
+1,511
| +6% | +$169K | 0.77% | 43 |
|
|
2021
Q2 | $3.83M | Buy |
23,636
+694
| +3% | +$112K | 0.97% | 40 |
|
|
2021
Q1 | $2.8M | Buy |
22,942
+5,080
| +28% | +$619K | 0.79% | 42 |
|
|
2020
Q4 | $2.74M | Buy |
+17,862
| New | +$2.74M | 0.84% | 41 |
|